Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04895696 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
A Phase 2 study of Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 2
- Development phase
- 268
- Enrollment target
- 20
- Study locations
NCT04895696: Active Phase 2 study of Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb.
NCT04895696 is a Phase 2 study of Systemic Lupus Erythematosus that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 268 participants, below the 378-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04895696, a Phase 2 study of Systemic Lupus Erythematosus, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 268 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE). The extension period will provide additional long-term safety and efficacy data and enable those participants initially randomized to placebo to receive treatment with Afimetoran.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Afimetoran
Study Locations (20)
Florida
- Local Institution - 0121 - Clearwater
- Local Institution - 0167 - Kissimmee
- Local Institution - 0122 - Orlando
- Local Institution - 0173 - Ormond Beach
- Local Institution - 0154 - Plantation
- Local Institution - 0137 - South Miami
- Local Institution - 0155 - Tamarac
California
- Local Institution - 0123 - Huntington Beach
- Local Institution - 0170 - La Jolla
- Local Institution - 0159 - La Palma
- Local Institution - 0172 - San Diego
- Local Institution - 0164 - Woodland Hills
Georgia
- Local Institution - 0160 - Atlanta
- Local Institution - 0205 - Suwanee
Alabama
- Local Institution - 0100 - Birmingham
Illinois
- Local Institution - 0146 - Orland Park
Kentucky
- Local Institution - 0187 - Hopkinsville
Louisiana
- Local Institution - 0171 - Baton Rouge
Maryland
- Local Institution - 0134 - Wheaton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 268 participants |
| Start Date | 2021-10-11 |
| Est. Completion | 2029-04-22 |
| Phase | Phase 2 |
What the registry record for NCT04895696 still lists
NCT04895696 is an interventional study that assigns participants to a tested intervention. The registered 268 participants enrollment target is mid-sized for trials with a published cap, below the 378-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (29% lower).
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04895696 names 20 study sites across 9 states, led by Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT04895696 about?
NCT04895696 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)". The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE). The extension period will provide additional long-term safety and efficacy data and enable those participants initially randomized to plac...
What is the current status of trial NCT04895696?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 268 participants. The study started on 2021-10-11. Estimated completion is 2029-04-22.
What conditions does trial NCT04895696 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT04895696?
The interventions under investigation include: Placebo (OTHER), Afimetoran (DRUG).
Who is sponsoring clinical trial NCT04895696?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04895696 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04895696's enrollment target sits among peer trials
268 34th of 99 higher than 66 of 99 other Systemic Lupus Erythematosus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
RECRUITING · Phase 2
-
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
RECRUITING · Phase 2
-
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
RECRUITING · Phase 2
-
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05000632 · 268 participants · NA
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
- NCT05797831 · 268 participants · Phase 2
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- NCT05997381 · 268 participants · NA
BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears
- NCT06233461 · 268 participants · Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI